本网站为了提高网站的便利性使用Cookie。
Cookie政策
同意
Font Size
S
M
L
Print
Print
咨询(English)
English
Japanese
我们的事业
研究开发
公司信息
关联公司
股东・投资者信息(English)
可持续发展(English)
What's New
Archives
2025/06/12
Nippon Kayaku announces IBTROZI
TM
approved in the U.S. for patients with advanced
ROS1
-positive Non-Small Cell Lung Cancer
2025/06/02
Presentation of new data from pivotal phase II clinical studies of taletrectinib, a novel ROS1 inhibitor, in patients with advanced
ROS1
-positive Non-Small Lung Cancer at ASCO 2025
2025/05/30
Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC
2025/05/08
Nippon Kayaku received MSCI ESG Ratings of AA for the second year
2025/03/03
Nippon Kayaku announces completion of marketing authorization application of a novel ROS1 inhibitor, taletrectinib, for use in patients with advanced
ROS1
-positive Non-Small Cell Lung Cancer in Japan
投资者关系
Archives
公司介紹視頻
NIPPON KAYAKU Group in Your Daily Life
Commemorating 100 Years of Sukima Ideas
PageTop